(Q30372127)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Jodie McVernon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Gunter Hartel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1

Terry Nolan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

13

Maria C Zambon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Neil T Formica

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Katja Höschler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Maryanne V Skeljo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Tanya Stoney

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Daphne C Sawlwin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Jillian Bennet

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

David Ryan

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Russell L Basser

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

English

0 references

publication date

16 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

6383-6391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18801398%20AND%20SRC:MED&resulttype=core&format=json

Vaccination strategies for an influenza pandemic.

14 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Pandemic H5N1 influenza vaccine development: an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Incidence of influenza in Ontario following the Universal Influenza Immunization Campaign.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Strategy for distribution of influenza vaccine to high-risk groups and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Mitigation strategies for pandemic influenza in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Statistical methods for assessing agreement between two methods of clinical measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Influenza vaccines in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

The challenges of vaccine responses in early life: selected examples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Transmission of influenza A in human beings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

The Australian response: pandemic influenza preparedness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

inferred from DOI database lookup

7 January 2021

based on heuristic

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046

inferred from DOI database lookup

7 January 2021

based on heuristic

The age pattern of mortality in the 1918-19 influenza pandemic: an attempted explanation based on data for England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.046